FDA Clearance Tracker · P160014
COBRA PzF NanoCoated Coronary Stent System
Last checked: Nov 19, 2026Latest source record: Feb 21, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Feb 21, 2017
Approval withdrawn
Time to decision
295 days
Received May 2, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P160014
- Device name
- COBRA PzF NanoCoated Coronary Stent System
- Applicant
- Celonova Biosciences, Inc.
- Applicant location
- San Antonio, TX
- Received
- May 2, 2016
- Decided
- Feb 21, 2017
- Decision
- Approval withdrawn
- Supplements
- 18 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- STENT, CORONARY (MAF)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the COBRA PzF NanoCoated Coronary Stent System is indicated for improving coronary luminal diameter in patients, including patients with diabetes mellitus, with symptomatic ischemic heart disease due to do novo lesions in native coronary arteries. The COBRA PzF Stent System is intended for use in patients eligible for percutaneous transluminal coronary angioplasty (PTCA) with a reference vessel diameter of 2.5-4.0 mm and lesion length of <24 mm.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MAF. The earliest in FDA's data is P910030, decided Feb 8, 1993.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Celonova Biosciences, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.